洞察市场格局
解锁药品研发情报

免费客服电话

18983288589
试用企业版

首页 临床进展 THE ROLE OF Ca 19-9, Ca 72-4, CEA AND CHOLESTEROL LEVELS IN PREDICTING MALIGNANCY IN GALLBLADDER POLYPS.

【ChiCTR2100047659】THE ROLE OF Ca 19-9, Ca 72-4, CEA AND CHOLESTEROL LEVELS IN PREDICTING MALIGNANCY IN GALLBLADDER POLYPS.

查看原文
立即下载
基本信息
登记号

ChiCTR2100047659

试验状态

结束

药物名称

/

药物类型

/

规范名称

/

首次公示信息日的期

2021-06-21

临床申请受理号

/

靶点

/

适应症

Gallbladder polyps

试验通俗题目

THE ROLE OF Ca 19-9, Ca 72-4, CEA AND CHOLESTEROL LEVELS IN PREDICTING MALIGNANCY IN GALLBLADDER POLYPS.

试验专业题目

THE ROLE OF Ca 19-9, Ca 72-4, CEA AND CHOLESTEROL LEVELS IN PREDICTING MALIGNANCY IN GALLBLADDER POLYPS.

申办单位信息
申请人联系人
申请人名称
联系人邮箱
联系人邮编

01000

联系人通讯地址
临床试验信息
试验目的

To determine a new algorithm in the diagnosis and treatment of gallbladder

试验分类
试验类型

连续入组

试验分期

探索性研究/预试验

随机化

Ninety patients (MAN/WOMAN) diagnosed with gallbladder polyp by abdominal ultrasonography between December 2017 and November 2020 were included in the study

盲法

N/A

试验项目经费来源

Writers

试验范围

/

目标入组人数

11

实际入组人数

/

第一例入组时间

2020-11-18

试验终止时间

2020-11-18

是否属于一致性

/

入选标准

Ninety patients diagnosed with gallbladder polyp by abdominal ultrasonography between December 2017 and November 2020 were included in the study；

排除标准

Patients who were diagnosed with polyps in an external center, whose cholesterol levels and tumor markers were not tested before the operation, and who had undergone previous interventional procedures to the gallbladder were excluded from the study.；

研究者信息
研究负责人姓名
试验机构

Nazmi OZER

研究负责人电话
研究负责人邮箱
研究负责人邮编

01000

联系人通讯地址
<END>

Nazmi OZER的其他临床试验

更多

土耳其Adana city training and research hospital General surgery department的其他临床试验

更多

最新临床资讯

更多
对摩熵医药数据库感兴趣，可以免费体验产品
体验产品